Increased diacylglycerol (DAG) levels are observed in numerous pathologies, including conditions associated with bone loss. However, the effects of DAG accumulation on the skeleton have never been directly examined. Because DAG is strictly controlled by tissue specific diacylglycerol kinases (DGKs), we sought to examine the biological consequences of DAG accumulation on bone homeostasis by genetic deletion of DGKζ, a highly expressed DGK isoform in osteoclasts (OCs).
Introduction
Diacylglycerol (DAG) is an important second messenger involved in a variety of cellular responses including proliferation, differentiation, motility and secretion (1) . DAG also acts as a precursor in the synthesis of triglycerides and certain membrane phospholipids (2) . Thus, tight spatial and temporal regulation of DAG must be achieved for signal specificity. Accumulating evidence suggests the existence of three separate pools of DAG, differing in their fatty acid compositions and independently regulated. The most significant source of DAG originates from the phospholipase C (PLC) family of enzymes, which produce DAG from either phosphatidylinositol (PI) or phosphatidylcholine (PC) (3) . Among them, PLCγ is known to generate DAG in response to receptor and non-receptor tyrosine kinases (3) . A second source of DAG comes from phosphatidic acid (PA) dephosphorylation (3) . Finally, the third source of DAG is generated by the activity of sphingomyelin synthases during the synthesis of sphingomyelin (3) . The fatty acid compositions of the DAGs formed by these various routes reflect the composition of the parent phospholipids and dictate the specificity of DAG-mediated effects in vivo (4) .
Bone loss is a key feature of numerous pathologies including osteoporosis, rheumatoid arthritis and bone metastases. Osteoclasts (OCs) are the specialized cells which resorb bone (5) . Evidence suggests that DAG plays an important role in regulating OCs. Genetic deletion of PLCγ2, the enzyme that converts PIP2 into IP3 and DAG in the OC, leads to an osteopetrotic bone phenotype due to blockade of OC differentiation (6, 7) . Ablation of DAG-dependent protein kinase C delta (PKCδ) leads to defective bone resorption and high bone mass (8) . Similarly, inhibitors of classical and novel PKCs reduce bone resorption in vitro and in vivo (9, 10) . Conversely, deletion of acyl-CoA-diacylglycerol acyltransferase (DGAT-1), the main catabolizing enzyme involved in DAG-mediated formation of triglycerides, leads to osteopenia owing to increased OC numbers (11) . All these findings indirectly suggest that DAG is an important regulator of osteoclastogenesis and/or bone resorption. However, the direct effects of DAG on the OCs and bone metabolism have not been yet elucidated. DAG is a small molecule and it cannot be targeted by traditional genetic knockout approaches. So far pharmacological approaches using the synthetic DAG analog, phorbol ester myristate (PMA), or exogenous DAG species have revealed conflicting results regarding bone resorption and OC formation (12) (13) (14) . Considering that increased diacylglycerol (DAG) levels are observed in conditions associated with bone loss, understanding the direct effects of DAG on the skeleton is mandatory but it requires an animal model of altered DAG metabolism.
Diacylglycerol kinases (DGK) are a class of enzymes that convert DAG into PA, thus providing strict modulation of DAG levels in the cell (15) . Ten isozymes exist, each showing unique tissue expression and distinct subcellular localization (15) . The diversity in expression, localization, and activity provides each DGK isoform the ability to modulate specific DAG species/pools and therefore to take part in different signaling axes (4, 15) . We have identified that DGKζ is highly expressed in macrophages and OCs. Thus, analysis of DGKζ−/− mice would allow us to answer these critical questions: is DAG directly involved in OC differentiation and, if so, how? Can altered DAG levels in OC lineage cells affect bone homeostasis? And what signaling pathways modulate DAG levels in the OC? Herein, we demonstrate that accumulation of DAG through DGKζ deletion leads to a substantial osteoporotic bone phenotype owing to increased OC numbers. Surprisingly, increased DAG contributes to upregulation of the osteoclastogenic transcription factor c-Fos in response to M-CSF but not RANKL. We also demonstrate that restoring DAG levels in PLCγ2 haploinsufficient OCs rescues OC formation and normalizes c-Fos expression. This is the first report to definitively establish the importance of this second messenger in OCs and thereby in bone homeostasis. Furthermore, our data also provide a paradigm shift demonstrating that M-CSF potently induces c-Fos expression through DAG production, thereby exacerbating OC differentiation in conditions where RANKL signaling alone would not have maximal effects.
Materials and methods

Mice
DGKζ −/− mice were kindly provided by Dr. Gary A Koretzky (Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, Ithaca, NY) and PLCγ2 +/− by Dr. JN Ihle (St. Jude Children's Research Hospital, Memphis, Tennessee, USA). All experiments were approved by the Washington University School of Medicine animal care and use committee. Male and female mice (C57BL/6 background), 4-8 weeks of age, were used in the study. Mice were housed in cages and were fed with food and water ad libitum, with a 12 h light and 12 h dark cycle.
Histology and in vivo μCT
Histological analysis was performed on five-micron longitudinal sections of fixed, decalcified, paraffin-embedded tibiae stained with TRAP to detect OCs. Osteoblast activity was assessed in calcein labelled, non-decalcified, methacrylamide embedded-sections. Analysis was performed using a Nikon Eclipse 80i microscope and a 20X objective lens. Quantitative histological parameters were assessed using the BIOQUANT OSTEO software (BIOQUANT Image Analysis Corporation, Nashville, TN). For in vivo analysis, mice were anesthetized with isoflurane and bones were scanned at an x-ray potential of 70kV, a current of 114 μA, an integration time of 100 ms and at a voxel size of 21 μm using the viva μCT40 scanner (Scanco Medical AG, Bassersdorf, Switzerland). Three-dimensional models were constructed and a trabecular region 0.5 mm below the growth plate of the distal femur extending 100 sections was analyzed in Scanco image analysis software, in accordance to standard guidelines (16) . All trabecular measurements were made by manually delineating cortical and trabecular bone, with an adaptive threshold of 155-255.
OC differentiation and bone resorption
Bone marrow was flushed from the long bones of 6-8 week old C57BL/6 WT or DGKζ −/− mice and cultured in α-minimum Eagle's medium (α-MEM; Sigma-Aldrich, St. Louis, MO) containing 5% heat-inactivated fetal bovine serum, glutamine and 1/50 volume CMG 14-12 culture supernatant as source of M-CSF (17) for 3 days to generate BMMs. For osteoclastogenesis, BMMs were further cultured in the presence of 100 ng/ml GST-RANKL (purified from BL21 with pGEX-6-RANKL plasmid, using HOOK GST protein purification kit, G-BIOSCIENCES, St. Louis, MO) and 25 ng/ml M-CSF (Sigma-Aldrich, St. Louis, MO) for an additional 3-5 days. For TRAP staining, cells were fixed in 4% paraformaldehyde and stained using the leukocyte acid phosphatase kit (Sigma-Aldrich). For bone resorption, BMMs were cultured on tissue culture plates in the presence of osteoclastogenic medium for 2 days, lifted, and replated in equal number on bone slices for additional 2 days. Cells were scraped and bones stained with 20 μg/ml peroxidaseconjugated wheat-germ agglutinin (Sigma-Aldrich) for 1h at room temperature, followed by incubation with 3,3′-diaminobenzidine (Sigma-Aldrich) for 30 min. Bone resorptive pits were analyzed using a light microscope (Nikon) and quantified using Image J software.
Real-time PCR
Total RNA was isolated using RNeasy mini kit (Qiagen). 1 μg of total RNA was reversetranscribed to cDNA using High Capacity cDNA Reverse Transcription Kit (life technologies, Grand Island, NY). For quantitative real-time PCR, SYBR Green PCR master mix (Life Technologies) and specific synthesized primers ((IDT Technologies, Coralville, IA) were used. The primer sequences are included in supplemental method table 1. mRNA expression levels were normalized to the respective cyclophilin A mRNA and the 2 −ΔΔCt method was used to determine the relative amounts of mRNA transcribed.
RANKL, M-CSF, PMA Stimulation and Immunoblotting
BMMs (cells in culture with 100ng/ml M-CSF) or preOCs (cells in culture with 100ng/ml RANKL and 25ng/ml M-CSF for 2-3 days) were serum and cytokine starved for 2 h and then stimulated with 100 ng/ml GST-RANKL, 100 ng/ml M-CSF or 1-500 nM PMA for the indicated times. In adhesion assays, cells were lifted and replated in equal numbers onto pRGD coated dishes for indicated times. Cells were harvested in lysis buffer containing protease-phosphatase inhibitor cocktail (Thermo SCIENTIFIC). To obtain nuclear extracts, cells were lysed with hypotonic buffer (10 mM HEPES, 1.5 mM MgCl 2 , 1 mM KCl, 1 mM DTT, and protease and phosphatase inhibitors) followed by the addition of 0.1% Nonidet P-40 (Sigma-Aldrich). After centrifugation, the supernatants were collected (cytosolic fraction), whereas the pellets (nuclear fraction) were suspended in high salt buffer (hypotonic buffer plus 400 mM NaCl). 25 μg of protein from each condition was subjected to immunoblotting. 1:500 dilutions of primary antibodies were used; DGKζ c-terminus (Santa Cruz Biotechnology, Dallas, Texas), actin, H3, GAPDH, IKBα, PKC isoforms, PKD2, ERK, JNK/SAPK, AKT, P38 and c-Fos (Cell Signaling Technology, Danvers, MA). Specific proteins were detected with Super Signal West Pico Chemiluminescent Substrate (Thermo SCIENTIFIC, Rockford, IL) and imaged using the SYNGENE chemiluminescent Imaging System (SYNOPTICS GROUP, Alexandria, VA).
AP1/c-Fos binding assay
Biotinylated complementary AP1 oligos (5′-CGCTTGATGACTCAGCCGGAA-3′) were synthesized (IDT Technologies, Coralville, IA) and annealed at 100 μM final concentration. 50 μl of biotinylated oligos were mixed with 100 μl streptavidin agarose beads (Sigma-Aldrich) for 1 h at 4°C, washed and re-suspended in 100 μl 1x binding buffer with DTT plus protease inhibitors. For c-Fos pull-down, 50 μg nuclear extract was mixed with 1 μl poly dIdC (1 μg/μl) (Sigma-Aldrich) and 5 μl AP1 oligo-beads. The mixture was rotated overnight at 4°C, washed, and resuspended in 50 μl 1x sample loading buffer (30 mM NaCl, 10 mM Tris pH7.4, 1 mM EDTA, 5% glycerol, 1 mg/ml BSA and β-Mercaptoethanol). The beads were boiled, and supernatants were subjected to immunoblotting.
Lipid extraction, liquid chromatography and mass spectrometry
BMMs were stimulated with 100 ng/ml M-CSF and homogenized in 600 μL of PBS using the Omni Bead Ruptor 24 (Omni International, Inc., Kennesaw, GA). A modified Bligh-Dyer extraction method (18) was used to extract lipids in the presence of internal standard DAG 15:0-15:0. Sample analysis was performed with a Shimadzu 10A HPLC system coupled to a TSQ Quantum Ultra triple quadrupole mass spectrometer operated in SRM mode under ESI (+). Data processing was conducted with Xcalibur software (Thermo SCIENTIFIC). The analyte concentration was calculated as the concentration of its corresponding internal standard multiplied by the peak area ratio of the analyte to the internal standard, based on the assumption that the MS responses of the analyte and internal standard are the same. The DAG species concentrations were normalized to respective DNA content.
Expression plasmids and transfection
Luciferase reporter genes, WT-c-Fos and ΔTRE-c-Fos plasmids were a gift from Dr. Ron Prywes (Department of Biological Sciences, Columbia University, New York, NY). Chimeric EpoR/c-Fms receptor construct, containing the external domain of erythropoietin fused to the cytoplasmic domain of M-CSF receptor, was a gift from Dr. Steven Teitelbaum (Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO). WT or mutant c-Fos luciferase reporters expressed in pGL3 vector and EpoR/c-Fms in pMX retrovirus vector were transiently transfected into HEK293T cells using PolyJet DNA in vitro Transfection Reagent (SignaGen Laboratories, Gaithersburg, MD). After 24 h the media was changed, cells were starved overnight, and stimulated with 100 nM PMA (Sigma-Aldrich), 5% serum or 100 ng/ml human recombinant erythropoietin (Sigma-Aldrich) for indicated time.
Lentiviral c-Fos shRNA knockdown
Two c-Fos lentiviral ShRNA constructs were designed and purchased from Washington University RNAI CORE (Saint Louis, MO). shRNA1 targets the sequence GCGGAGACAGATCAACTTGAA (nucleotides 638 to 658) and shRNA2 CCTGTCAACACACAGGACTTT (nucleotides 266 to 286) of c-Fos mRNA (NCBI accession number NM_010234.2). Briefly, the c-Fos shRNAs (alone or in combination) or control shRNA (targeting LacZ sequence CGACCACGCAAATCAGCGATT) were co-transfected with the packaging plasmid (psPAX2) and the envelope plasmid (pMD2.G) into HEK293T cells. Medium containing the lentivirus was harvested 48 hrs after transfection, filtered, and was used to infect DGKζ−/− BMMs cultured in osteoclastogenesis medium (containing 100 ng/ml RANKL and 25 ng/ml M-CSF) to assess OC differentiation. A parallel set of cells was used to confirm c-Fos knocked-down by Western blot analysis.
Statistics
Data were analyzed using the GraphPad PRISM 5 software (GraphPad Software, Inc. La Jolla, CA). Student's t-test was performed to determine the statistic P values of experimental data compared to a reference. P less than 0.05 was considered to be statistically significant.
Results
DGKζ is expressed in osteoclasts and controls bone homeostasis
To evaluate the importance of DAG in modulating bone homeostasis, we turned to the DGK family of kinases, which upon activation convert DAG into PA (19) . Thus, removal of critical DGKs would allow us to examine the biological effects of increased DAG levels on bone mass. We first examined expression of all ten DGK isoforms by qRT-PCR in bone residing cells. DGKζ is highly expressed in BMMs and OCs ( Figure 1A ), although its levels gradually decrease in mature OCs compared to their precursors ( Figure 1B ). DGKζ is also expressed to a lesser extent in osteoblasts, T cells, neutrophils, and dendritic cells. Analysis of DGKζ protein levels reveals both cytoplasmic and nuclear localization. Short-term stimulation with M-CSF or RANKL, two cytokines that induce macrophage proliferation and OC differentiation respectively, does not alter the protein distribution ( Figure 1C Figure 1A-B) . Thinning of the cortical bone is also observed in DGKζ −/− mice versus WT ( Figure 2B ; cortical thickness in μm WT: 0.134±0.01; KO: 0.104±0.01; p<0.001). Bone histomorphometric analysis of tartrate-resistant acid phosphatase (TRAP) stained tibia sections from 6 weeks old mice reveals increased OC number normalized to bone surface in the trabecular bone of KO mice compared to WT ( Figure 2C , D p = 0.01) as well as increased number of OCs on the cortical bone ( Figure 2E ; p<0.01). Ex-vivo μCT analysis performed in the 6 weeks old set of mice confirms the osteoporotic bone phenotype detected by viva-CT (not shown). Because DGKζ is also expressed at low levels in osteoblasts, next we determined whether decreased osteoblast function might also contribute to the osteoporotic bone phenotype of DGKζ −/− mice. To this end, we measured bone formation rates (BFR) and mineralization apposition rates (MAR) in 4 week-old mice following two consecutive calcein injections at a 5 day interval. Our analysis reveals no differences between WT and DGKζ −/− animals in OB activities (Supplemental Figure 2A-B) . Furthermore, mRNA levels of RANKL, OPG and M-CSF isolated from snap-frozen long bones are similar in both WT and KO mice, thus indicating that DGKζ deficiency impacts bone mass primarily by targeting intrinsic pathways in the OCs (Supplemental Figure 2C) .
DGKζ deficiency increases osteoclast differentiation and bone resorption
To further characterize the DGKζ −/− OC phenotype, we turned to our in vitro culture system. DGKζ −/− BMMs form larger and more numerous OCs than WT in the presence of RANKL (100 ng/ml) and M-CSF (25 ng/ml) ( Figure 3A-B) . To assess OC functionality, we plated equal numbers of committed OCs (BMMs cultured in osteoclastogenic cytokines for 3 days) on bone slices for 48 h and resorptive area was measured following cell removal by peroxidase-conjugated wheat-germ agglutinin staining. Presence of equal numbers of OC was confirmed by counting the numbers of actin rings, the functional OC unit, prior to removal of the cells (Supplemental Figure 3) . DGKζ −/− OCs show a 2.5-fold increase in the percentage of resorbed area, demonstrating a higher resorptive capacity than WT ( Figure  3C ). In agreement with the above observations, qRT-PCR analysis shows a significant increase in markers of OC differentiation (NFATc1, TRAP, Calcitonin receptor, c-Fos), fusion (DC-STAMP, ATP6V0D2), and function (Cathepsin K, MMP-9) in DGKζ −/− cultures compared to WT ( Figure 3D ).
To exclude that the higher rate of osteoclastogenesis in DGKζ −/− cultures is dependent on increased proliferation of precursor cells, we plated equal numbers of committed OCs (BMMs cultured in osteoclastogenic cytokines for 3 days) in the presence of different concentrations of M-CSF and a fixed amount of RANKL. Higher numbers of DGKζ −/− OCs form at every dose of M-CSF tested ( Figure 3E ). Taken together, these results indicate that DGKζ is a negative regulator of osteoclastogenesis.
DGKζ controls PKC activation in response to integrin-mediated adhesion
Next, we analyzed signaling pathways activated in DGKζ deficient cells that could account for enhanced OC differentiation and resorption. Among DAG downstream effectors, novel and classical PKC members control MAPK and NF-κB activation in various cell types, as well as integrin mediated-responses. Thus, we measured phosphorylation of various PKC isoforms, MAPKs, and the negative regulator of NF-κB, namely IκBα, in response to RANKL and M-CSF. We also analyzed nuclear translocation of classical and alternative NF-κB subunits, p65 and Rel-B, in WT and DGKζ −/− BMMs stimulated with the two osteoclastogenic cytokines. Surprisingly, no major differences in the above pathways are noted between the two genotypes in response to either cytokine (Supplemental Figure 4 , and Supplemental Figure 5) . Interestingly, however, activation of PKC pathway, detected by the pan-phospho PKC antibody, and phosphorylation of the novel PKC isoform PKCδ, are increased in DGKζ −/− BMMs plated on pRGD, an integrin substrate (Supplemental Figure 6 ). Considering the importance of PKCδ in the bone resorptive process (8) , this result suggests that DGKζ deficiency controls OC activity, but not OC formation, via DAGmediated PKC activation.
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, whose activation is dependent on PLCγ2 pathway (6) . Thus, we hypothesized that DGKζ deficiency may increase osteoclastogenesis by modulating c-Fos levels. We found that c-Fos levels are elevated in OC cultures from DGKζ −/− cells compared to WT (not shown). Since c-Fos is an immediate early gene, that can be rapidly induced in response to stimuli (23) , we also measured c-Fos induction in WT and DGKζ −/− BMMs stimulated with RANKL or M-CSF. RANKL exposure leads to similar levels of c-Fos expression in WT and DGKζ −/− cells ( Figure 4A ). To our surprise, M-CSF induces higher and prolonged accumulation of c-Fos in both the cytoplasm and nucleus of DGKζ −/− cells ( Figure 4B-C) .
To directly compare the effects of RANKL and M-CSF on c-Fos levels, WT and DGKζ −/− preOCs were incubated with both cytokines alone or in combination for one hour. c-Fos protein levels are significantly lower in cells stimulated by RANKL compared to M-CSF in both genotypes ( Figure 4D ). Interestingly, no further induction of c-Fos over the levels induced by M-CSF is observed in response to both cytokines together. Importantly, while RANKL-mediated c-Fos induction is similar in the two genotypes, M-CSF, alone or in combination with RANKL, induces a much stronger elevation of c-Fos in DGKζ −/− cells compared to WT.
The ability of c-Fos to recognize and bind to consensus sequences in chromosomal DNA is essential to drive osteoclastogenesis (24) . To investigate whether M-CSF induces c-Fos binding to the DNA in a DAG-dependent manner, equal concentrations of nuclear lysates from RANKL-and M-CSF-stimulated WT and DGKζ −/− preOCs were incubated with biotinylated labeled AP1 double-stranded oligonucleotides. While c-Fos/AP1 association is no different upon RANKL stimulation, the binding of c-Fos to AP1 oligos after M-CSF exposure is higher in DGKζ −/− cells compared to WT ( Figure 4E-F) .
M-CSF induces c-Fos upregulation via DAG
To determine whether DAG controls c-Fos expression in OC precursors, BMMs were treated with various concentrations of the non-hydrolyzable DAG analog PMA. Exposure to PMA rapidly induces c-Fos in both WT and DGKζ −/− cells in a dose-dependent manner ( Figure 5A ), suggesting that c-Fos is directly downstream of DAG signaling. We further confirmed that PMA can potently induce c-Fos expression by using a WT c-Fos luciferase reporter construct in HEK293T cells and show a similar increase in luciferase expression following PMA and serum as control ( Figure 5B ).
Having found that DAG can induce c-Fos expression, next we measured DAG levels in WT and DGKζ −/− OC precursors stimulated with M-CSF or RANKL using liquid chromatography-mass spectrometry (LC/MS). M-CSF induces the generation of diverse DAG species, containing both saturated and unsaturated fatty acyl chains. Experiments were performed in triplicate using three different sets of mice per genotype and data were pooled together and expressed as fold change induction compared to unstimulated cells. Higher levels of DAG with Oleic/Palmitic, Palmitic/Palmitoleic, Stearic/Oleic, Oleic/Oleic, and Stearic/Arachidonic fatty acyl chains are observed in M-CSF-treated DGKζ −/− cells compared to WT ( Figure 5C ). Interestingly, RANKL exposure only minimally affects the generation of DAG species compared to M-CSF in both genotypes ( Figure 5C ). DGKζ deficiency does not alter Palmitic-Eicosenoic, Palmitic-Stearic or Palmitic/Palmitic DAG species neither in response to RANKL or M-CSF (supplemental Figure 7) . All together, these data further demonstrate that DGKζ regulates DAG levels in response to M-CSF and not RANKL in the OC.
To further investigate the mechanism by which M-CSF-mediated DAG production promotes c-Fos expression, we turned to the c-Fos promoter region. This region harbors four enhancer elements, which respond to a variety of growth factors, cytokines, and small molecules (25) . One of these regions, the TRE site, has been shown to activate c-Fos transcription in response to DAG analogs (26) . Thus, we hypothesized that the TRE region is responsible for the activation of c-Fos in response to M-CSF. Due to technical difficulties in generating primary BMMs expressing c-Fos luciferase reporter constructs, we transfected HEK293T cells with a luciferase reporter construct containing the full-length c-Fos promoter (WT-Fos) or lacking the TRE region (ΔTRE-Fos), a mutant known to abrogate c-Fos expression in response to DAG (25) . Cells were also co-transfected with a chimeric M-CSF receptor (c-Fms), containing the intracellular tail of c-Fms and the extracellular domain of the erythropoietin receptor (EpoR), thus enabling us to study M-CSF-dependent induction of c-Fos in this model. Double transfected cells were then stimulated with erythropoietin (Epo) for 3-6 hours to activate c-Fms signaling. After 3 hour stimulation, cells expressing ΔTRE-Fos show approximately 50% less luciferase activity in response to Epo than cells expressing WT-Fos, and this difference is more striking following 6 hour Epo stimulation ( Figure 5D ). Taken together, these results indicate that DAG production and the TRE site in the c-Fos promoter region are required for optimal expression of c-Fos by M-CSF.
DGKζ deficiency rescues the PLCγ2 +/− osteoclast differentiation defect by increasing c-Fos levels
Next, to demonstrate that DGKζ deficiency promotes osteoclastogenesis via DAG-mediated c-Fos induction, we used 2 different approaches. Our first approach consisted of knocking down c-Fos in DGKζ −/− BMMs. We used 2 c-Fos shRNA lentiviral constructs, alone or in combination, or control shRNA. Cells were then cultured for 7 days with RANKL and M-CSF to induce OC differentiation and western blot for c-Fos expression was performed at the end of the experiment. We find a dose-dependent inhibitory effect of c-Fos knockdown on osteoclastogenesis in DGKζ null cultures ( Figure 6A-B) , thus demonstrating that c-Fos is required for OC differentiation in the absence of DGKζ.
Our second approach consisted on targeting DGKζ in PLCγ2 deficient OC cultures. We have previously shown that PLCγ2, an enzyme that converts PIP2 into IP3 and DAG, is required for OC formation (6, 8, 27) via upregulation of NFATc1 and c-Fos transcription factors. Thus, we hypothesized that genetic deletion of DGKζ in the PLCγ2 −/− background could rescue osteoclastogenesis through increasing DAG levels and restoring c-Fos expression. We were unsuccessful in generating DGKζ −/− ; PLCγ2 −/− mice due to embryonic lethality, however, DGKζ −/− ; PLCγ2 +/− mice are viable. As previously reported (6), PLCγ2 +/− BMMs form fewer and poorly spread OCs compared to WT and display reduced NFATc1 and c-Fos expression ( Figure 6C-D) . Notably, genetic deletion of DGKζ −/− in PLCγ2 +/− cultures rescues OC formation and c-Fos expression, without affecting NFATc1 levels ( Figure 6C-D) . These data demonstrate that DAG is an important regulator of osteoclastogenesis downstream of the PLCγ pathway via modulation of c-Fos levels.
Discussion
Although DAG production occurs downstream of numerous signals known to control bone mass (6, 23, 28, 29) , its role in bone homeostasis or whether increased DAG levels contribute to bone fragility or osteopenia has never been investigated. Our study demonstrates that the accumulation of DAG in the OC has deleterious consequences for the maintenance of healthy bone mass.
Investigating the in vivo role of DAG has been extremely difficult because of its short halflife (30, 31) . In addition, genetic deletion of this second messenger cannot be achieved, and pharmacological approaches using synthetic DAG or non-hydrolyzable compounds (i.e. PMA) may not provide an accurate representation of the complex nature of DAG signaling. To overcome this caveat, we turned to DGKζ, the enzyme that catabolizes DAG to PA (19) , which is highly expressed by OC precursors. Accumulation of DAG in DGKζ −/− OC precursors leads to severe osteopenia due to accelerated OC differentiation. Surprisingly, DAG does not appear to regulate signaling pathways downstream of the RANK/RANKL axis but modulates M-CSF-dependent activation of the osteoclastogenic transcription factor c-Fos (Model in Figure 7) . These findings establish the role of DAG as a significant regulator of bone mass via its actions in the OCs and further expand the current role of M-CSF beyond cell proliferation and survival, demonstrating its importance in OC differentiation. M-CSF and RANKL are key osteoclastogenic cytokines.
M-CSF provides proliferative and survival cues, while RANKL governs OC maturation (32) (33) (34) . Both cytokines induce activation of PLCγ, a class of hydrolytic enzymes that generate DAG (6, 35) . We have previously shown that loss of PLCγ2 leads to severe osteopetrosis (6, 7) . While the main mechanism of OC dysfunction in the context of PLCγ2 deficiency has been primarily attributed to impaired calcium-mediated NFATc1 expression, our new data suggest an additional mechanism of PLCγ2-mediated regulation of osteoclastogenesis through DAG signaling. Indeed, we demonstrate that impaired OC differentiation in PLCγ2 haploinsufficient mice can be rescued by deletion of DGKζ, which increases DAG levels and restores defective c-Fos expression, while NFATc1 levels remain unaltered. These findings stress the importance of DAG-mediated signaling during the OC differentiation process. While our study indicates that the pool of DAG metabolized by DGKζ controls osteoclastogenic pathways downstream of M-CSF, we cannot exclude that additional DAG pools, generated through other pathways, could modulate osteoclastogenesis and bone homeostasis. For example, mice lacking DGAT-1, an enzyme involved in DAG-mediated synthesis of triglycerides, develop osteopenia due to increased OC differentiation (11) . Although the authors did not fully investigate the mechanism by which DGAT-1 deficiency induces accelerated osteoclastogenesis, our findings would suggest that increased DAG levels in DGAT-1 −/− OC precursors might be responsible for this phenotype.
Previous studies on the role of DAG in OCs, including ours, have focused on targeting downstream DAG effectors, such as classical and novel PKC family members. These reports indicated that inhibiting PKC activation impairs OC resorptive activity (8, 10) . Similarly, we observe that phosphorylation of PKCδ is increased in DGKζ −/− cells compared to WT in response to adhesion to an integrin substrate. This result is in agreement with the importance of PKCδ in the bone resorptive process and provides important insights into the mechanism by which DGKζ deficiency may regulate bone resorption. However, activation of PKCδ is highly unlikely to be responsible for increased osteoclastogenesis, as PKCδ −/− OCs develop normally (8) . Indeed, we did not find differences in PKC phosphorylation between DGKζ −/− and WT cells in response to RANKL and M-CSF, suggesting an alternative mechanism for DAG effects during osteoclastogenesis. This result was unexpected since studies in other cell types lacking DGKζ, such as T cells and cardiomyocytes, showed that increased PKC activation was responsible for T cell development and cardiac dysfunction, respectively (36, 37) . Interestingly, it has been reported that activation of PKCα in response to increased calcium levels decreases its sensitivity to further activation by DAG (38) . Thus, it is possible that increased calcium oscillations during osteoclastogenesis drive PKC activation in the OC and prevent DAG from inducing further activation of the kinase. Recent reports have also suggested that the functional significance of DAG is not restricted to PKC pathway, and DAG also activates several proteins including Ras GRP, protein kinase D, and transient receptor potential proteins that could account for DAG specific effects in the cell (1) . Nevertheless, this finding left us with the remaining question: how does accumulation of DAG control OC differentiation independently of PKC? c-Fos is a critical transcription factor involved in OC differentiation, whose expression increases during the early stages of osteoclastogenesis, and can also be rapidly regulated by stimuli. c-Fos knockout mice develop a severe osteopetrotic phenotype due to absence of OCs (20) . The current paradigm places expression of c-Fos primarily downstream of RANKL (22) . Surprisingly, in this study we demonstrate that M-CSF, but not RANKL, induces maximal c-Fos upregulation through DAG production. Our findings also reveal that RANKL is a weaker inducer of c-Fos expression than M-CSF, and that RANKL does not provide further additive effects over the optimal levels of c-Fos induced by M-CSF alone. Perhaps the most surprising aspect of this finding is that although both cytokines could generate DAG via activation of PLCγ, only M-CSF utilizes this second messenger to induce c-Fos transcription. Accumulating evidence suggests the existence of separate pools of DAG, different in their fatty acyl compositions and independently regulated. For example, only DAG molecules that contain unsaturated fatty acyls (oleic, linoleic, linolenic) are able to activate PKC, whereas DAGs containing saturated fatty acyls (such as palmitic and stearic) cannot (39) . We find that M-CSF produces high levels of DAG containing stearic/ arachidonic, oleic-oleic, stearic-oleic and oleic-palmitic acyls in WT cells, and the levels are even higher in DGKζ −/− cells. Surprisingly, our data also show that RANKL produces very low levels of these DAG species, at least at the time points tested in our experiments, and that DAG levels are similar in both WT and KO cells. This important observation supports the notion that DGKζ specifically controls the DAG pool generated downstream of M-CSF in the OC.
Another possible explanation for the distinct requirement of DAG during c-Fos transcription is that RANKL and M-CSF activate different PLCγ isoforms, which could further explain why M-CSF and RANKL have different effects on the generation of DAG species. We previously demonstrated that RANKL activates PLCγ2 to induce osteoclastogenesis and PLCγ1 does not compensate for lack of PLCγ2 in this process (6) . We also observed that M-CSF, but not RANKL, activates PLCγ1 (6) and its deletion by shRNA arrests osteoclastogenesis, despite normal expression levels of PLCγ2 (data not shown). While PLCγ2 controls NFATc1 in response to RANKL, it is plausible that PLCγ1 is activated downstream of M-CSF to generate DAG species involved in c-Fos expression. This assumption is further supported by the observation that DGKζ deletion in PLCγ2 +/− preOCs rescues osteoclastogenesis by normalizing c-Fos but not NFATc1 levels.
Regulatory sequences in the c-Fos promoter have been extensively studied (26) . Among them, the TRE site has been shown to activate c-Fos transcription in response to DAG analogs (26) . In agreement with this observation, we show that PMA increases c-Fos protein levels in preOCs. More importantly, we demonstrate that M-CSF induces luciferase activity in HEK293T cells transfected with a full-length c-Fos promoter. M-CSF-triggered effects on c-Fos luciferase activity are significantly reduced in cells expressing the ΔTRE-c-Fos promoter. Unfortunately, we could not perform this experiment in primary BMMs because of technical difficulties in expressing luciferase constructs in primary cells. Nevertheless, the result from the luciferase assay in HEK293T cells, in conjunction with the data showing higher DAG and c-Fos levels in DGKζ −/− cells following M-CSF, but not RANKL, treatment support the importance of the M-CSF/DGKζ/DAG axis on regulation of c-Fos levels during osteoclastogenesis.
We have previously found that high doses of M-CSF, rather than increased RANKL concentrations, can overcome the OC differentiation defects in the context of αvβ3, Vav and Syk deficiencies; all pathways upstream of PLCγ1 and PLCγ2 activation (40) (41) (42) . We have also observed that exposure to high concentrations of M-CSF increases ERK phosphorylation and rescues c-Fos expression in αvβ3 −/− cells (40) . Although not measured at that time, it is plausible that high doses of M-CSF generate higher levels of DAG required for optimal c-Fos expression. Our previous observations together with our current findings demonstrate that M-CSF not only supports precursor survival and proliferation, but also controls OC differentiation through a different mechanism than RANKL. Elevated M-CSF levels are observed in various pathologies associated with bone loss, such as rheumatoid arthritis (43) (44) (45) (46) . Considering that increased DAG species can also induce T cell hyperactivity (36, 37) , as observed in mice lacking DGKζ and DGKα, targeting DAG production in rheumatic conditions could have beneficial effects for both the inflammatory and osteolytic components of the disease.
In conclusion, we demonstrate that augmented DAG levels in the OC have a profound impact on bone mass. To our knowledge, this is the first report positioning DAG, and its regulatory kinase DGKζ, as critical regulators of osteoclastogenesis in vitro and in vivo and also suggests that altered DAG levels in disease conditions such as diabetes should be considered as a potential mechanism for abnormal bone homeostasis. 
